Xlife Sciences AG / Key word(s): PatentXlife Sciences: Swiss portfolio company Axenoll receives strategically significant patent by the European Patent OfficeTitle 20.01.2023 / 07:00 CET/CESTXlife Sciences AG (SIX: XLS) announced today that its Swiss portfolio company Axenoll Life Sciences AG has been granted a stra.
Xlife Sciences AG / Key word(s): MiscellaneousXlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS) 16.01.2023 / 07:00 CET/CESTXlife Sciences' (SIX: XLS) portfolio company inflamed pharma has launched a research project to develop a potential th.
16.01.2023 - Xlife Sciences AG / Key word(s): Miscellaneous Xlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS) 16.01.2023 / 07:00 CET/CEST Xlife Sciences (SIX: XLS) portfolio company . Seite 1
<p><span>In a difficult macroeconomic environment, SIX Swiss Exchange ensured stable trading and efficient capital raising. Trading activity remained close to last year’s levels while the Swiss Market Index SMI® declined by 16.7%. Facilitating capital raising with new offerings, SIX Swiss Exchange recorded fourteen company listings, including its first ever Sparks and nine GDRs listings. In addition, nine new product issuers and six trading participants joined in 2022.</span></p>
Xlife Sciences AG / Key word(s): MiscellaneousPortfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CESTLysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Scienc.